Search Results
Jul 09, 2026, 08:00 ET Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting
(i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue
More news about: Astellas Pharma Inc.
Jul 09, 2026, 07:27 ET Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The
More news about: Cardiol Therapeutics Inc.
Jul 09, 2026, 07:17 ET Cool Off With Summer Savings at Natural Grocers®, July 16-18, 2026
[iii]Offer valid on 7/17/2026 from 12-2 p.m. local
More news about: Natural Grocers by Vitamin Cottage, Inc.
Jul 09, 2026, 06:30 ET Hyperscale Data Surpasses 1,000 Bitcoin in Corporate Treasury
strong corporate treasury can provide financial flexibility while we continue building a leading AI infrastructure company," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "We are investing simultaneously in digital assets, AI data centers, robotics and high-performance compute because
More news about: Hyperscale Data Inc.
Jul 09, 2026, 05:28 ET InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
the China National Medical Products Administration (NMPA). InxMed is progressing its clinical development plan, including an ongoing randomized Phase III confirmatory trial (NCT07174908) intended to support the adoption of this all‑oral, chemotherapy-free regimen as a new standard of care in the front‑line
More news about: InxMed Co., Ltd
Jul 09, 2026, 05:14 ET NNS adquiere acciones de OCI
riesgos relacionados con la obtención de aprobaciones regulatorias sin demoras o condiciones imprevistas y la posibilidad de acciones regulatorias; (iii) riesgos relacionados con costes significativos relacionados con la transacción; (iv) el desempeño financiero y operativo esperado y las oportunidades
More news about: NNS Holding (Cyprus) Limited
Jul 09, 2026, 03:31 ET WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.WuXi Biologics regards
More news about: WuXi Biologics
Jul 09, 2026, 02:35 ET Combining SEGRO and Prologis - A Credible Path to Value Creation
reject any proposed transaction with Prologis; (ii) uncertainties as to whether SEGRO will cooperate with Prologis regarding any proposed transaction; (iii) the effect of the announcement of any proposed transaction on the ability of Prologis and SEGRO to operate their respective businesses and retain and
More news about: Prologis, Inc.
Jul 08, 2026, 23:00 ET Sempra Infrastructure's ECA LNG Phase 1 Exports First LNG Cargo from Mexico's Pacific Coast
to, as applicable, (i) being able to reach a positive final investment decision, (ii) negotiating pricing and other terms in definitive contracts, (iii) completing construction projects or other transactions on schedule and budget, (iv) realizing anticipated benefits from any of these efforts if completed,
More news about: Sempra Infrastructure
Jul 08, 2026, 21:13 ET HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
cancer.InxMed brings a complementary profile. Its lead asset, IN10018/ifebemtinib, has advanced into late-stage clinical development, including a Phase III trial in China for platinum-resistant recurrent ovarian cancer, and has received Fast Track designation from the U.S. FDA. Its pipeline focuses on tumor
More news about: HanchorBio Inc.
Jul 08, 2026, 20:30 ET Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
discoveries into clinical assets. Most notably, Rentosertib (ISM001-055)—the world's first AI-empowered, first-in-class drug candidate, recently entered Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).Additional clinical milestones include:Garutadustat
More news about: Insilico Medicine
Jul 08, 2026, 16:15 ET FS Credit Opportunities Corp. (FSCO) Declares Distribution for July 2026
these funds, including uncalled investor capital commitments from which Future Standard is currently not earning management fees or carried interest; (iii) the value of outstanding CLOs (excluding CLOs wholly-owned by Future Standard); (iv) the fair value of FS KKR Capital Corp. joint venture (JV) assets
More news about: Future Standard
Jul 08, 2026, 16:15 ET FS Specialty Lending Fund (FSSL) Declares Distribution for July 2026
these funds, including uncalled investor capital commitments from which Future Standard is currently not earning management fees or carried interest; (iii) the value of outstanding CLOs (excluding CLOs wholly-owned by Future Standard); (iv) the fair value of FS KKR Capital Corp. joint venture (JV) assets
More news about: Future Standard
Jul 08, 2026, 16:05 ET NAPCO Announces Executive Leadership Transition
and the Company undertakes no duty to update such information, except as required under applicable law.Contact: Francis J. Okoniewski IIIVice President of Investor Relations NAPCO Security Technologies, Inc. 800-645-9445 x 374 Mobile: 516-404-3597
More news about: NAPCO Security Technologies, Inc.
Jul 08, 2026, 14:55 ET NNS erwirbt Anteile an OCI
im Zusammenhang mit dem Erhalt behördlicher Genehmigungen ohne unerwartete Verzögerungen oder Auflagen sowie die Möglichkeit behördlicher Maßnahmen; (iii) Risiken im Zusammenhang mit erheblichen Kosten der Transaktion; (iv) die erwartete finanzielle und operative Entwicklung sowie zukünftige Chancen nach
More news about: NNS Holding (Cyprus) Limited
Jul 08, 2026, 14:53 ET NNS acquiert des actions d'OCI
risques liés à l'obtention des autorisations réglementaires sans retards ni conditions imprévus, ainsi que la possibilité de mesures réglementaires ; (iii) les risques liés aux coûts importants associés à l'opération ; (iv) les performances financières et opérationnelles attendues ainsi que les opportunités
More news about: NNS Holding (Cyprus) Limited
Jul 08, 2026, 14:42 ET Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
therapies for solid tumor cancers, announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax®-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of
More news about: Northwest Biotherapeutics, Inc.
Jul 08, 2026, 14:32 ET The Inner Circle acknowledges John P Avant as a Pinnacle Professional Member Inner Circle of Excellence
extensive professional training and certifications, including teacher certification through the Roger Williams University Career Technical Program, Level III Instructor certification from the National De-escalation Training Center at the University of New Haven, Certified Youth Mentor training through MENTOR
More news about: The Inner Circle
Jul 08, 2026, 14:24 ET Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
therapies for solid tumor cancers, announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax®-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of
More news about: Northwest Biotherapeutics, Inc.
Jul 08, 2026, 13:38 ET NNS acquires shares in OCI
at all; (ii) risks relating to the receipt of regulatory approvals without unexpected delays or conditions and the possibility of regulatory action; (iii) risks relating to significant costs related to the transaction; (iv) the expected financial and operating performance and future opportunities following
More news about: NNS Holding (Cyprus) Limited
Jul 08, 2026, 13:33 ET NNS acquires shares in OCI
at all; (ii) risks relating to the receipt of regulatory approvals without unexpected delays or conditions and the possibility of regulatory action; (iii) risks relating to significant costs related to the transaction; (iv) the expected financial and operating performance and future opportunities following
More news about: NNS Holding (Cyprus) Limited
Jul 08, 2026, 10:30 ET 5W AI City Index 2026: San Francisco #1, London #2, Beijing #3, Tel Aviv #4.
82.0Seoul — 78.7Tier II (ranks 7–14) includes Paris, Boston, Abu Dhabi, Shanghai, Toronto, New York, Dubai, and Shenzhen. Tier III (ranks 15–25) includes Berlin, Hyderabad, Tokyo, Bangalore, Riyadh, Stockholm, Amsterdam, Los Angeles, Zurich, Montreal, and Sydney.Six numbers
More news about: 5W Public Relations
Jul 08, 2026, 10:21 ET Octapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years
https://doi.org/10.1182/blood-2024-206631 iii Connell NT, Flood VH, Brignardello-Peterson R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv.
More news about: Octapharma
Jul 08, 2026, 10:11 ET Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
characterizations.The Breaking PointOn February 19, 2026, Grail revealed that the primary endpoint of a statistically significant reduction in Stage III and IV cancers "was not observed." The Company attributed this failure, in part, to probably needing "a longer follow-up time." The admission that the
More news about: Levi & Korsinsky, LLP
Jul 08, 2026, 09:51 ET 德州南方大學推出全面校園總規劃
策略計劃及籌備百年校慶。 計劃概述未來十年約 17 億美元的校園投資，以及超過 20 個分期推行的項目。 此規劃使未來資本投資與大學的策略重點保持一致，並採取經周詳規劃的智慧增長方式，以支持學生成就、人才培育、研究拓展和社區參與，確保院校長遠有效運作。校長 J. W. Crawford III 表示：「隨著德州南方大學持續向前發展，設施及基礎建設投資必須支持預期成果，這一點至關重要。 總規劃使校園實體發展與院校策略重點互相配合，提供可隨時間逐步擴展的穩固框架。」校園總體規劃是在德州南方大學社群及社區持份者共同參與下制定，既為未來發展提供路線圖，亦保留大學的歷史特色、推進其使命，並隨時代及情況變化保持靈活性。總體規劃列出一系列相互連繫、分階段推行的資本項目，以支持學生成就、人才培育、研究拓展及社區參與。
More news about: Texas Southern University